David Nikodem (Metadeq, GBR)

David Nikodem (Metadeq, GBR)

(Speaker)
David joined Metadeq Diagnostics as CEO in January 2023 to lead the company to commercialization stage. Prior, David was CEO of AltheaDx, Inc., a San Diego-based diagnostics company focused on pharmaco-genomics (PGx) in depression & anxiety. At AltheaDx, David orchestrated a corporate restructuring, successfully gained Medicare Coverage and re-launched the company’s lead test kit, IDgenetix. In April 2022, Castle Biosciences (NASDAQ: CSTL) completed an acquisition for AltheaDx. David holds undergraduate degrees in chemistry, and English language and literature from the University of Virginia, and a Ph.D. in biochemistry and molecular biology from Georgetown University. He conducted basic science research at the National Institutes of Health for 3 years and also was a patent examiner at the United States Patent and Trademark Office in Washington, D.C. He resides in Orlando, Florida with his wife and two children and maintains family roots with a home in Chevy Chase, Maryland.